Technical Analysis for VRNA - Verona Pharma plc
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Historical VRNA trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bollinger Band Squeeze | Range Contraction | 0.00% | |
| Doji - Bullish? | Reversal | 0.00% | |
| BB Squeeze + Lower Band Touch | Range Contraction | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Lower Bollinger Band Touch | Weakness | 0.00% | |
| Bollinger Band Squeeze | Range Contraction | -1.35% | |
| NR7 | Range Contraction | -1.35% | |
| Doji - Bullish? | Reversal | -1.35% | |
| Bollinger Band Squeeze | Range Contraction | -3.38% | |
| BB Squeeze Started | Range Contraction | -3.38% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| 60 Minute Opening Range Breakdown | about 23 hours ago | |
| Lower Bollinger Band Support | about 24 hours ago | |
| Down 3% | 1 day ago | |
| Down 2 % | 1 day ago | |
| Down 1% | 1 day ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 09/27/2019
- Sector: Healthcare
- Industry: Biotechnology
Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The companys lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma. Verona Pharma plc is based in London, the United Kingdom.
Respiratory Therapy Asthma Cystic Fibrosis Chronic Obstructive Pulmonary Disease Respiratory Diseases Lactams Pulmonology Treatment Of Chronic Obstructive Pulmonary Disease
Respiratory Therapy Asthma Cystic Fibrosis Chronic Obstructive Pulmonary Disease Respiratory Diseases Lactams Pulmonology Treatment Of Chronic Obstructive Pulmonary Disease
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 15.71 |
| 52 Week Low | 2.01 |
| Average Volume | 2,174,612 |
| 200-Day Moving Average | 5.56 |
| 50-Day Moving Average | 7.27 |
| 20-Day Moving Average | 7.03 |
| 10-Day Moving Average | 6.90 |
| Average True Range | 0.53 |
| ADX | 17.63 |
| +DI | 16.10 |
| -DI | 21.91 |
| Chandelier Exit (Long, 3 ATRs ) | 6.72 |
| Chandelier Exit (Short, 3 ATRs ) | 7.60 |
| Upper Bollinger Band | 7.67 |
| Lower Bollinger Band | 6.40 |
| Percent B (%b) | 0.14 |
| BandWidth | 18.01 |
| MACD Line | -0.15 |
| MACD Signal Line | -0.09 |
| MACD Histogram | -0.0589 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 7.31 | ||||
| Resistance 3 (R3) | 7.28 | 7.01 | 7.18 | ||
| Resistance 2 (R2) | 7.01 | 6.82 | 7.02 | 7.14 | |
| Resistance 1 (R1) | 6.79 | 6.71 | 6.66 | 6.82 | 7.10 |
| Pivot Point | 6.52 | 6.52 | 6.45 | 6.53 | 6.52 |
| Support 1 (S1) | 6.30 | 6.33 | 6.17 | 6.33 | 6.04 |
| Support 2 (S2) | 6.03 | 6.22 | 6.04 | 6.00 | |
| Support 3 (S3) | 5.81 | 6.03 | 5.96 | ||
| Support 4 (S4) | 5.84 |
